Status:

COMPLETED

Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Collaborating Sponsors:

European and Developing Countries Clinical Trials Partnership (EDCTP)

The Research Council of Norway

Conditions:

HIV Infections

Eligibility:

All Genders

5-9 years

Phase:

PHASE3

Brief Summary

The ANRS 12174 study is a clinical trial that will compare the efficacy and safety of prolonged infant peri-exposure prophylaxis (PEP) with Lopinavir/Ritonavir (LPV/r) versus Lamivudine to prevent HIV...

Eligibility Criteria

Inclusion

  • A baby will be included if she/he:
  • is a singleton
  • is breastfed at day 7 by her/his mother and her/his mother intends to continue breastfeeding for at least 6 months
  • has a post-partum blood sample with a negative HIV-1 DNA PCR test result at day 7 (+/- 2 days)
  • has received ART as part of PMTCT
  • and if the mother:
  • has reached the local legal age for participating in medical research studies
  • is shown to be HIV-1 infected (with or without HIV-2 infection) and is not eligible for HAART or is not taking HAART
  • has received a perinatal antiretroviral prophylaxis during pregnancy and delivery,
  • has a CD4 count above the threshold of HAART initiation in pregnant women according to the national recommendation in each site (minimum 230 cells/µL),
  • resides within the study area and is not intending to move out of the area in the next year
  • gives assent for the infant to participate and gives consent to participate

Exclusion

  • S/he presents clinical symptoms and/or biological abnormalities equal to or greater than grade II of the ANRS classification for adverse event on the day of enrolment
  • S/he presents with serious congenital malformation(s)
  • Her/his birth weight is lower than 2.0 kg
  • Her/his antiretroviral prophylaxis is extending beyond day 7
  • The mother has participated in the trial for a previous pregnancy
  • S/he and her/his mother are participating in another clinical trial on the day of enrolment

Key Trial Info

Start Date :

December 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2014

Estimated Enrollment :

1500 Patients enrolled

Trial Details

Trial ID

NCT00640263

Start Date

December 1 2009

End Date

February 1 2014

Last Update

April 14 2014

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Université de Ouagadougou

Ouagadougou, Burkina Faso

2

East London Hospital Complex

East London, South Africa

3

Dept of Paediatrics and Child Health, Makerere University

Kampala, Uganda

4

Dept of Paediatrics and Child Health, School of Medicine, University of Zambia

Lusaka, Zambia

Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding | DecenTrialz